Cargando…

Correction: New score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059520/ https://www.ncbi.nlm.nih.gov/pubmed/32201593 http://dx.doi.org/10.1136/openhrt-2018-000931corr1

Ejemplares similares

New score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs
por: Rutherford, Ole-Christian Walter, et al.
Publicado: (2018)

Intraocular Bleeding in Patients With Atrial Fibrillation Treated With NOACs VS. Warfarin: A Systematic Review and Meta-Analysis
por: Liu, Fuwei, et al.
Publicado: (2022)

Erratum to: NOACs for secondary stroke prevention in patients with atrial fibrillation
Publicado: (2020)

Nine-Year Trends in Prevention of Thromboembolic Complications in Elderly Patients with Atrial Fibrillation Treated with NOACs
por: Bielecka, Bernadetta, et al.
Publicado: (2022)

NOACs vs. Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation
por: Patel, Priya, et al.
Publicado: (2017)

Access Site Bleeding Complications with NOACs versus VKAs in Patients with Atrial Fibrillation Undergoing Cardiac Implantable Device Intervention
por: Spinoni, Enrico Guido, et al.
Publicado: (2022)

Author Correction: A new risk score to assess atrial fibrillation risk in hypertensive patients (ESCARVAL-RISK Project
por: Orozco-Beltran, Domingo, et al.
Publicado: (2023)

Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non–Vitamin‐K Oral Anticoagulants (RAF‐NOACs) Study
por: Paciaroni, Maurizio, et al.
Publicado: (2017)

Effectiveness and Safety of NOAC Versus Warfarin in Patients With Atrial Fibrillation and Aortic Stenosis
por: Melgaard, Line, et al.
Publicado: (2021)

The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation
por: O'Brien, Emily C., et al.
Publicado: (2015)

Management and outcomes of real-world use of non-vitamin-K oral anticoagulants (NOACs) in patients with atrial fibrillation: experience of a dedicated NOAC clinic
por: de Veer, A. J. W. M., et al.
Publicado: (2019)

Are NOACs as safe and efficient as VKA regarding thromboembolic prophylaxis and major bleeding in patients with surgical bioprosthesis and atrial fibrillation within 3 months of surgery?
por: Magro, Pedro Lamares, et al.
Publicado: (2022)

Oral anticoagulation following bioprosthetic SAVR in patients with atrial fibrillation: what’s the current status of NOACs?
por: Milojevic, Milan, et al.
Publicado: (2022)

Post-TAVR patients with atrial fibrillation: are NOACs better than VKAs?—A meta-analysis
por: Wang, Lu, et al.
Publicado: (2023)

Do NOACs Improve Antithrombotic Therapy in Secondary Stroke Prevention in Nonvalvular Atrial Fibrillation?
por: Lin, Yi-Pin, et al.
Publicado: (2015)

Bleeding Risk Scores in Atrial Fibrillation: Helpful or Harmful?
por: Edmiston, Marissa K., et al.
Publicado: (2018)

Baseline characteristics and event rates among anticoagulated patients with atrial fibrillation in practice and pivotal NOAC trials
por: Noseworthy, Peter A., et al.
Publicado: (2017)

Concomitant Use of NSAIDs or SSRIs with NOACs Requires Monitoring for Bleeding
por: Lee, Min-Taek, et al.
Publicado: (2020)

Gastrointestinal Bleeding Due to NOACs Use: Exploring the Molecular Mechanisms
por: Saviano, Angela, et al.
Publicado: (2022)

Correction to: Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis
por: Sakuma, Ichiro, et al.
Publicado: (2019)

Assessment of treatment patterns and patient awareness in atrial fibrillation patients using non-vitamin K antagonist oral anticoagulants (ASPECT-NOAC)
por: Badak, Özer, et al.
Publicado: (2022)

Do Patients with Atrial Fibrillation and a History of Ischemic Stroke Overuse Reduced Doses of NOACs?—Results of the Polish Atrial Fibrillation (POL-AF) Registry
por: Szyszkowska, Anna, et al.
Publicado: (2022)

Comparing clinical outcomes of NOACs with warfarin on atrial fibrillation with Valvular heart diseases: a meta-analysis
por: He, Qiyu, et al.
Publicado: (2019)

Cost-benefit analysis of VKA versus NOAC treatment in German patients with atrial fibrillation utilizing patient self-testing
por: Diel, Roland, et al.
Publicado: (2019)

Correction to: Fine Fibrillatory Wave as a Risk Factor for Heart Failure Events in Patients With Atrial Fibrillation: The Fushimi Atrial Fibrillation (AF) Registry
Publicado: (2022)

Acute Stroke and Atrial Fibrillation: Risk of Incorrect NOAC Dosage When Estimating Renal Function From Plasma Creatinine Only
por: Amoey, Danial C., et al.
Publicado: (2022)

The Reversal of Bleeding Caused by New Oral Anticoagulants (NOACs): A Systematic Review and Meta-Analysis
por: Udayachalerm, Sariya, et al.
Publicado: (2018)

Correction: Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation
Publicado: (2022)

Correction: Stroke prevention of thoracoscopic left atrial appendage clipping in patients with non-valvular atrial fibrillation at high risk of stroke and bleeding: study protocol for a non-randomised controlled clinical trial
Publicado: (2023)

Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry
por: Renda, Giulia, et al.
Publicado: (2020)

Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs
por: Komen, Joris, et al.
Publicado: (2017)

Stroke and Bleeding Risk Assessments in Patients With Atrial Fibrillation: Concepts and Controversies
por: Ding, Wern Yew, et al.
Publicado: (2020)

Stroke and Bleeding Risk in Atrial Fibrillation
por: Senoo, Keitaro, et al.
Publicado: (2014)

Assessing bleeding risk in 4824 Asian patients with atrial fibrillation: The Beijing PLA Hospital Atrial Fibrillation Project
por: Guo, Yu-tao, et al.
Publicado: (2016)

Lack of reversibility for NOACs
por: Al-Kindi, Sadeer
Publicado: (2014)

TAVR: nemesis of NOACs?
por: Polzin, Amin, et al.
Publicado: (2022)

A comparison of the effects of NOAC and VKA therapy on the incidence of dementia in patients with atrial fibrillation: A systematic review and meta‐analysis
por: Wang, Wenjie, et al.
Publicado: (2023)

Efficacy and safety of NOAC versus warfarin in AF patients with left atrial enlargement
por: Wu, Victor Chien-Chia, et al.
Publicado: (2020)

Assessing Adherence and Persistence to Non-vitamin K Antagonist Oral Anticoagulants (NOACs) among Patients with Atrial Fibrillation in Tertiary-care Referral Centers in Malaysia
por: Kubas, Mohammed A, et al.
Publicado: (2020)

Correction: Relationship of CHA(2)DS(2)-VASc and CHADS(2) Score to Left Atrial Remodeling Detected by Velocity Vector Imaging in Patients with Atrial Fibrillation
por: Li, Yihui, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_njbismkfbg9u4viv8bu8c9j7lq